Dechra trading in line with expectations

7th Jul 2009 07:56

Dechra Pharm, pharmaceutical firm focused on the veterinary sector, said trading for the year to June is in line with management's expectations.Group revenues are ahead by approximately 15% in comparison with last year."The group continues to perform robustly in challenging economic conditions. Although our markets have experienced a slower rate of growth, we have demonstrated solid progress compared to last year," said the group.The group said its product development pipeline continues to deliver results. Revenue from pharmaceutical division increased by approximately 57.5% compared to last year.Its manufacturing business, Dales® Pharmaceuticals, performed well during the period due to improved efficiency and increased production of both our own and third party products."With new product launches imminent and increased penetration of existing markets, we remain confident about the future growth prospects of the group," added the group.